## CGP-53353

MedChemExpress

| Cat. No.:          | HY-108600   |           |                               |
|--------------------|---|-----------|-------------------------------|
| CAS No.:           | 145915-60-2   | 2         |                               |
| Molecular Formula: | C <sub>20</sub> H <sub>13</sub> F <sub>2</sub> N <sub>3</sub> O | 2         |                               |
| Molecular Weight:  | 365.33  |           |                               |
| Target:            | PKC; DNA/R  | RNA Synth | nesis                         |
| Pathway:           | Epigenetics   | ; TGF-bet | a/Smad; Cell Cycle/DNA Damage |
| Storage:           | Powder  | -20°C     | 3 years                       |
|                    |   | 4°C       | 2 years                       |
|                    | In solvent  | -80°C     | 6 months                      |
|                    |   | -20°C     | 1 month                       |

## SOLVENT & SOLUBILITY

In Vitro

\* "≥" means soluble, but saturation unknown.

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|-------------------------------|-----------|------------|------------|
|                              | 1 mM                          | 2.7373 mL | 13.6863 mL | 27.3725 mL |
|                              | 5 mM                          | 0.5475 mL | 2.7373 mL  | 5.4745 mL  |
|                              | 10 mM                         | 0.2737 mL | 1.3686 mL  | 2.7373 mL  |

| BIOLOGICAL ACTIV          | ІТҮ  |                                     |  |
|---------------------------|--|-------------------------------------|--|
| Description               | CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC <sub>50</sub> s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-<br>53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for<br>researching atherosclerosis of diabetic patients <sup>[1]</sup> .  |                                     |  |
| IC <sub>50</sub> & Target | ΡΚCβΙΙ<br>0.41 mM (IC <sub>50</sub> )  | ΡΚCβΙ<br>3.8 mM (IC <sub>50</sub> ) |  |
| In Vitro                  | CGP-53353 (DAPH-7) (1 μM; 48-96 hours) inhibits glucose-induced cell proliferation in A10 cells <sup>[1]</sup> .<br>CGP-53353 (1 μM ; 0-48 hours) inhibits the glucose-induced increase and acceleration of DNA synthesis in A10, also blocks<br>the glucose-induced increase of S-phase cell percentage <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |                                     |  |
|                           | Cell Proliferation Assay   |                                     |  |

## **Product** Data Sheet

HN

N H NH

()) O

| Cell Line:       | A10 (cell proliferation induced by glucose) <sup>[1]</sup>   |
|------------------|--|
| Concentration:   | 1μM  |
| Incubation Time: | 48-96 hours  |
| Result:          | Inhibited glucose-induced cell proliferation, although A10 cell proliferation was stimulated by increasing glucose concentrations. |

## REFERENCES

[1]. Yamamoto M, et al. Acute glucose-induced downregulation of PKC-betaII accelerates cultured VSMC proliferation. Am J Physiol Cell Physiol. 2000;279(3):C587-C595.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA